Clinical advancement of hypercoagulability in patients with ovarian cancer
10.3969/j.issn.1007-3969.2015.03.012
- VernacularTitle:卵巢癌患者血液高凝状态临床研究进展
- Author:
Zheng FENG
;
Hao WEN
;
Xiaohua WU
- Publication Type:Journal Article
- Keywords:
Ovarian cancer;
Hypercoagulability;
Interleukin-6
- From:China Oncology
2015;(3):231-234
- CountryChina
- Language:Chinese
-
Abstract:
The incidence of venous thromboembolism in patients with ovarian cancer is much higher than other gynecologic cancers. Approximate 20%of ovarian cancer patients have hypercoagulable status during different phases of their disease. Ovarian cancer itself can induce hypercoagulability, but meanwhile the over activated coagulation system may promote disease progression. Coagulation system disorder is one of the most important prognostic factors in ovarian cancer. Recently, hypercoagulability becomes a hot spot in the ovarian cancer research ifeld. This article reviews the mechanism of hypercoagulability, its clinical implication and correlated treatment in ovarian cancer patients.
